Table 2.
Association between XRCC1 polymorphisms and the RFS of the patients
| Epirubicin | MMC | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||
| Recurrence | Total | MST* | P logrank | Adjusted HR (95% CI) | Recurrence | Total | MST* | P logrank | Adjusted HR (95% CI) | |
| rs915927 | ||||||||||
| AA | 35 | 93 | 24.6 | 0.020 | 1.00 (reference) | 31 | 92 | 25.3 | 0.784 | 1.00 (reference) |
| AG | 12 | 32 | 44.5 | 0.21 (0.08-0.53) | 7 | 17 | 35.0 | 0.68 (0.26-1.75) | ||
| GG | 1 | 4 | 15.8 | 1.40 (0.16-11.99) | 1 | 2 | 86.5 | 0.66 (0.08-5.54) | ||
| AA | 35 | 93 | 24.6 | 0.009 | 1.00 (reference) | 31 | 92 | 25.3 | 0.700 | 1.00 (reference) |
| AG+GG | 13 | 36 | 41.3 | 0.24 (0.10-0.59) | 8 | 19 | 40.4 | 0.68 (0.28-1.65) | ||
| rs2854501 | ||||||||||
| CC | 38 | 96 | 24.4 | 0.002 | 1.00 (reference) | 31 | 91 | 25.2 | 0.753 | 1.00 (reference) |
| CT | 8 | 28 | 45.8 | 0.10 (0.03-0.35) | 7 | 18 | 35.0 | 0.66 (0.26-1.67) | ||
| TT | 2 | 5 | 29.4 | 0.65 (0.14-3.10) | 1 | 2 | 86.5 | 0.66 (0.08-5.47) | ||
| CC | 38 | 96 | 24.4 | 0.001 | 1.00 (reference) | 31 | 91 | 25.2 | 0.586 | 1.00 (reference) |
| CT+TT | 10 | 33 | 43.3 | 0.16 (0.06-0.43) | 8 | 20 | 40.2 | 0.66 (0.27-1.60) | ||
*
Mean survival time.